Details of the Drug
General Information of Drug (ID: DMH1M6N)
| Drug Name | 
                     ORG2058 
                 | 
            ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms | 
                                         
                        IJLXLZGJDSJGIQ-BILPMHSYSA-N; Org-2058; Org 2058; CHEMBL2311103; 24320-06-7; (8R,9S,10R,13S,14S,16R,17S)-16-ethyl-17-(2-hydroxyacetyl)-13-methyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-one; O-2058; [3H]ORG2058; [3H]-ORG2058; A)-16-ethyl-21-hydroxy-19-norpregn-4-ene-3,20-dione; AC1Q6OBA; AC1L3O6Q; SCHEMBL3273165; GTPL3454; GTPL3453; 16alpha-Ethyl-21-hydroxy-19-nor-4-pregnene-3,20-dione; BDBM50422735; (16alpha)-16-Ethyl-21-hydroxy-19-norpregn-4-ene-3,20-dione; 19-Norpregn-4-ene-3,20-dione,; ORG-2058; ORG 2058
                        
                     
                                     | 
            ||||||||||||||||||||||
| Indication | 
                                                            
  | 
            ||||||||||||||||||||||
| Drug Type | 
                     Small molecular drug 
                 | 
            ||||||||||||||||||||||
| Structure | 
                    ![]()  | 
            ||||||||||||||||||||||
| 3D MOL is unavailable | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 344.5 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 3.8 | ||||||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 3 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 3 | ||||||||||||||||||||||
| Chemical Identifiers | 
                        
  | 
                ||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT)  | 
                
                    
  | 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
![]() Drug Off-Target (DOT)  | 
                
                    
  | 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Molecular Interaction Atlas (MIA) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||||||||
                    
  | 
            ||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||
References



